Palvella Therapeutics: Funding, Investors & Team (Oct 2026)
Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.
Palvella Therapeutics has raised $243M across 5 funding rounds on record, the most recent an undisclosed round of $200M announced in Feb 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Palvella Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Palvella Therapeutics Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
Palvella Therapeutics raised $37.7M in a Series D announced in Jan 2023.
1.8 years later, an undisclosed round of $2.6M was announced in Oct 2024.
2 months later, an undisclosed round was announced in Dec 2024 with no disclosed amount.
10 months later, an undisclosed round of $2.6M was announced in Oct 2025.
4 months later, an undisclosed round of $200M was announced in Feb 2026.
Palvella Therapeutics Founders and Leadership Team
Contact details for the Palvella Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Palvella Therapeutics Funding Compared to Other Biotechnology Startups
Palvella Therapeutics' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Palvella Therapeutics in Biotechnology and Wayne
Companies Similar to Palvella Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Palvella Therapeutics Funding FAQs
What does Palvella Therapeutics do?
Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.
How much funding has Palvella Therapeutics raised?
Palvella Therapeutics has raised $243M across 5 rounds on record. The most recent is an undisclosed round of $200M announced in Feb 2026.
When did Palvella Therapeutics last raise funding?
Palvella Therapeutics' most recent funding round on record is an undisclosed round of $200M, announced in Feb 2026.
Who founded Palvella Therapeutics?
FundedIQ lists Wes Kaupinen (Founder), Wesley Kaupinen (Founder) at Palvella Therapeutics.
Where is Palvella Therapeutics headquartered?
Palvella Therapeutics is based in Wayne, Pennsylvania, United States.
How many employees does Palvella Therapeutics have?
Palvella Therapeutics is in the 1-10 employee band.
How does Palvella Therapeutics' funding compare to other Biotechnology startups?
Palvella Therapeutics' latest round of $200M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Palvella Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Palvella Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.